Allocation of IPO proceeds to human resources, R&D, DX and working capital
First written in FY2021. 2 of 4 entries say "Restated". Latest entry: FY2023.
47 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「The Group's main funding needs in its business activities are investment funds for capital investment and research and development in the Group's manufacturing business, as well as repayment of acquisition financing for LBO financing in the business succession business.」
The Group continues to manage capital investment, R&D and repayment of LBO financing as its main funding needs. - FY2022RestatedAnnual report
「Funds obtained from financing activities amounted to ¥770.801 million. This was mainly due to ¥1,127 million in proceeds from long-term borrowings associated with the establishment of a new plant by a consolidated subsidiary and ¥1,014.707 million in proceeds from the issuance of shares through the public offering and other transactions.」
The disclosure recorded financing results including funds raised through the public offering and other transactions and borrowings for the new plant. - FY2022-Q1AdvancedAnnual report
「As a result, share capital amounted to ¥1,102.030 million and the total number of issued shares was 4,356,780. / ⑦ Use of proceeds: The proceeds are planned to be used for working capital.」
In addition to the public offering, the third-party allotment on 28 July 2021 was completed, advancing the Company's capital raising. The proceeds from the third-party allotment were designated for working capital. - FY2021First statedAnnual report
「The proceeds are planned to be used to secure and train candidates for professional management positions, invest in R&D and DX, and fund working capital.」
The stated use of proceeds from the public offering of 850,000 new shares, with total proceeds of ¥883.660 million, was recorded.